Previous studies reported that EGFR-TKI resistance is associated with YAP overexpression or YAP amplification, and silencing YAP by siRNA can reverse EGFR-TKI resistance in NSCLC cells [40, 118]. Here, EGFR is linked to non-small cell lung carcinoma.